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Receptor status and gene amplification were studied in 
advanced human ovarian adenocarcinoma tissues, borderline 
and benign ovarian tumours and normal ovarian tissues. Sixty- 
five percent (53/82) of ovarian adenocarcinomas, 57% (8/ 14) of 
benign/borderline tumours and only zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA3 I xwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAYo (5/ 16) of normal 
ovarian tissues studied showed specific lz5I-EGF (epidermal 
growth factor) binding (median: 17; 10;  and 0 fmol EGF-R/mg 
protein, respectively) and a significant increase in progesterone 
receptor (PgR) levels was observed in these groups (median: 5; 
33; and I52 fmol/mg protein, respectively). No correlations 
were observed between the levels of EGF-R and the levels of 
either oestrogen receptors (ER) or PgR. All membrane samples 
of 25 adenocarcinomas studied by Scatchard analysis were 
positive for insulin-like growth-factor- I receptors (IGF- I -R) and 
contained higher IGF- I -R levels than membranes of I0 normal 
ovarian tissues, of which 9 were positive (median: 64 and 26 
fmol IGF- I -R/mg membrane protein, respectively). Also, as 
measured by autoradiography, 37 adenocarcinoma tissues 
showed a higher expression of IGF-I-R (1.5+ to 4+) than 
sections derived from I0 normal ovarian tissues (I +). 1251-IGF- I 
binding was predominantly associated with epithelial tumour 
cells, the surrounding connective tissue was negative and in 
several samples high expression of IGF- I -R was found in areas of 
tumour necrosis. Southern blot analysis of DNAs isolated from 
25 ovarian adenocarcinomas revealed no amplification of the 
IGF- I z xwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA-R or the EGF-R gene. The HERZ/neu gene was amplified 
only in 2 out of 3 histologically confirmed endometrioid adeno- 
carcinomas studied but not in 22 other tumours. An amplifica- 
tion of the c-myc gene was observed in 28% (7/25) of the 
tumours. All c-myc-amplified tumours were PgR-negative. No 
rearrangement was observed for any of the genes studied. In 
conclusion, ovarian adenocarcinoma tissues show a decrease in 
PgR levels and an increased expression of IGF-I -R and EGF-R, in 
the absence of gene amplification, when compared to benign/ 
borderline ovarian tumours and normal ovarian tissues. In 
addition, amplification of the c-myc and HER2/neu genes, 
without rearrangement of these genes, occurs in a minority of 
these tumours. 
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Ovarian cancer is the leading cause of death from gynaeco- 
logical cancers. Epidemiological studies show that there are 
relationships between the incidence of breast, endometrial 
and ovarian cancer. The vast majority of these female reproduc- 
tive cancers are of epithelial and not of stromal origin. Steroid 
hormone receptors are found in the tumour cells of these 
malignancies (Slamon et al., 1989). Hormones and growth 
factors involved in menstrual activity are the likeliest candi- 
dates for the aetiology of female reproductive cancers. Analy- 
ses have shown that histologic grade, stage of the disease, 
ploidy and age of the patient appear to influence disease-free 
survival in ovarian cancer (Rao and Slotman, 1991). Neverthe- 
less, additional (prognostic) factors in these cancers are 
needed to define the appropriate treatment for the individual 
patient. In recent years much attention has been focused on 
the role of growth factors and the activation of oncogenes in 
the development of human malignancies. Hormone receptor, 
growth-factor receptor and oncogene status appeared to be of 
importance with respect to clinical outcome of breast cancer 
(Foekens et al., 1991; Klijn et al., 1992; Berns et al., 1992). For 
instance, increased expression of epidermal growth factor 
receptor (EGF-R, c-erbB-1) was associated with poor progno- 
sis in primary breast tumours (Sainsbury etal., 1987). However, 
the role of the EGF-R as a prognostic factor in subgroups of 
breast cancer patients is still under debate (reviewed by Klijn et 
al., 1992). The c-erbB-2 gene (HER2 or neu). which shows 
extensive homology but is distinct from the c-erbB-1 gene, was 
shown to be amplified or over-expressed in approximately 20% 
of human mammary tumours (reviewed by: Maguire and 
Greene, 1989). It was suggested that amplification of the 
c-erbB-2 gene was a bad prognostic indicator in node-positive 
breast-cancer patients (Slamon et al., 1987), whereas amplifica- 
tion of another oncogene, c-my, may be of prognostic value 
for patients with node-negative or steroid-receptor-positive 
breast cancer (Berns et al., 1992). Data on another membrane- 
bound growth-factor receptor, the insulin-like growth factor-1 
receptor, are scarce in human primary breast cancer (reviewed 
by Foekens et ul., 1991). Studies on prognostic factors in 
ovarian cancer are limited. Data on EGF-R (c-erbB-1) expres- 
sion and prognosis in ovarian cancer have been reported 
(Battaglia et al., 1989; Bauknecht et al., 1990; Berchuck et al., 
1991). Amplification (Slamon et al., 1989) and over-expression 
(Berchuck et al., 1990) of HER2/neu/c-erbB-2 in primary 
tumours suggest a worse prognosis for patients with ovarian 
cancer. The role of c - m y  amplification and IGF-1-R in 
ovarian cancer is, as yet, unclear. 
The similarities between human breast and ovarian cancer 
prompted us to study the incidence and role of steroid 
hormones, growth factors, their receptors and oncogene- 
amplifications in ovarian carcinogenesis. We have studied the 
incidence and amount of IGF-1-R, using radioligand binding 
assays on membrane preparations and/or autoradiography on 
cryostat sections. The results were compared with those from 
non-epithelial ovarian tumours, benign and borderline malig- 
nancies and normal ovarian tissues. In addition, the incidences 
of EGF-R, ER and PgR and (onco-)gene amplification were 
assessed because these factors could be important in tumorigen- 
esis and may eventually assist in a better discrimination 
between high- and low-risk ovarian cancer patients. 
MATERIAL AND METHODS 
Patients arid tissues 
Tissues of ovarian carcinomas, benign and borderline ovar- 
ian tumours and normal ovaries were collected between 1988 
and 1989 in our cancer centre. Tissue samples were placed on 
ice immediately after excision, transported to the laboratory at 
a temperature below -70°C and stored in liquid nitrogen or at 
-70°C. The mean age of the patients from whom normal 
ovarian tissue was obtained was 63 (range: 47-79) and the 
mean age of the patients with ovarian tumours was 56 (range: 
26 to 78). Following the WHO classification (1973) these 
carcinomas were subtyped into: serous (n = 44), mucinous 
(14), endometrioid (8), clear-cell (7),  mixed (8) and poorly 
differentiated adenocarcinomas (10). The remaining samples 
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were subtyped as adenomas of borderline malignancy (9), 
adenomas (5). adenofibroma (I) ,  fibrothecomas (3), granulosa 
cell tumours (3) and malignant teratoma, intermediate type 
Receptor ussavs 
Tumour tissue (0.4-0.8 zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAg) was ground and homogenized as 
recommended by the EORTC for processing of breast tumour 
tissue for cytosolic ER and PgR determinations (EORTC 
Breast Cancer Cooperative Group, 1980). The homogenate 
was centrifuged for 30 min at 100,000 zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAg at 4"C, and the 
supernatant fraction (cytosolic extract) was used for E R  and 
PgR determinations, either with enzyme immunoassays (ER- 
EIA and PgR-EIA kits, Abbott, Abbott Park, IL) or with 
radioligand binding assays. The E R  and PgR values shown are 
those obtained from the EIAs, after establishing that data 
obtained with the EIAs on cytosols from ovarian adenocarcino- 
mas significantly correlated with those of the conventional 
biochemical assays (Spearman correlation: Rs = 0.81 for E R  
and Rs = 0.89 for PgR. respectively; for both 2p < 0.001, 
n = 31). The membrane fraction for EGF-R and IGF-1-R 
dcterminations was obtained in the supernatant fraction after 
re-homogenization of the 100,000g pellet in 2.5 ml BBB-buffer 
(20 mM phosphate buffer p H  7.4, containing 0.15 M NaCl and 
70 ygiml Bacitracin) on ice with 3 5-sec bursts at 20,000 rpm of 
an Omni-1000 tissue homogenizer (OMNI, Waterbury, CT). 
The homogenate was centrifuged for 10 min at 1,00Og, and the 
supernatant was used as membrane preparation. After an 
aliquot had been taken for membrane-protein determination, 
I .  19% (w/v) bovine serum albumin (BSA, purified, Behring- 
werke, Marburg, Germany) in BBB-buffer was added to a final 
concentration of 0.1% (w1v) BSA. Aliquots (100 yl) of cell 
membrane preparations were incubated with 8 concentrations 
(ranging from 0.15 to 3.5 nM) of 1251-mEGF tracer in a final 
volunic of 140 yl for 16 hr at 20°C. Non-specific binding was 
assessed in duplicate using 0.75 nM 1?51-mEGF and a 250-fold 
excess of non-labelled mEGF. Iodinated mEGF (specific 
activity 500-600 Ciimmol), prepared by Protag-125 or Enzymo- 
beads as described in detail by Kienhuis zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAet al. (1991) was kindly 
provided by Dr. Th.J. Benraad (Sint Radboud Hospital, 
Nijmegen, The Netherlands). Separation of bound and free 
ligand was performed using hydroxylapatite (HAP) adsorption 
(Benraad and Foekens. 1990), with minor modifications. A 
membrane protein threshold of 0.2 mg/ml was adapted to 
avoid possible false-negative results. Scatchard analysis of 
specific 12'I-IGF-1 (S.A. 2000 Ci1mmol: human-Thrs9-analog, 
Amcrsham, Aylesbury, UK) binding was performed after 
separation of bound and free ligand by high-speed centrifuga- 
tion zyx vutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAa s  described previously (Foekens et al., 1989). 
Autoradiography 
Frozen tissue sections (5 km) originating from 37 human 
ovarian carcinomas and 9 normal ovaries were stored at -70°C 
for up to 5 days. Prior to the assay, the slides were brought to 
room temperature and pre-incubated for 10 min in a PBS 
solution containing Bacitracin (40 pgiml) and BSA (0.5%); 
BBB-buffer. 
For IGF-1 receptor autoradiography, the cryostat sections 
were incubated with BBB-buffer containing 100 pM 1'51-IGF-l 
with or without a 1,000-fold molar excess of unlabeled IGF-I 
for 2 hr at room temperature. After incubation, the sections 
were washed 4 times with BBB buffer and subsequently dipped 
in water and acetone. The sections were air-dried at room 
temperature and placed against Hyperfilm 3H (Amersham). 
Slides were exposed for 3 days and the Hyperfilm was 
processed according to the manufacturer's instructions. 
Slides were scored as 1 + (indicating weak specific receptor 
presence) to 4+ (indicating strong specific receptor presence). 
Sections of onc of a few breast tumour specimens, which were 
negative for IGF-1 receptors in Scatchard plot analysis of 
(MTI) ( 1 ) .  
membrane preparations (151214: 7%, Foekens zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAef ul., 1989), 
were used as a negative control. Human placenta was used as a 
positive control tissue. 
DNA analysis 
DNA was isolated from an aliquot of the total tissue 
homogenate. Southern blotting of EcoR1-digested DNA was 
performed by standard techniques (Berns et al., 1992). In brief, 
digested DNA was size-fractionated on a 0.6% agarose gel and 
transferred to a nylon membrane (Hybond N Plus, Amersham) 
and hybridized overnight at 65°C with randomly primed, 
32P-dATP-labelled probes (specific activity of 1-2 x 10" cpmikg 
DNA). EGF-R (EGF receptor probe pHER-A 64-I), HER21 
rieu (pHER2-436-1, ATCC 59296); c-myc, an EcoR1-Clal 
human exon 3-specific c-niyc; and IGF-1-R (pIGF-9-R.8, 
ATCC 59295) were obtained from ATCC (Rockville, MD). 
After washing at high stringency (0.3 x SSC), autoradiography 
with intensifying screens was performed for 1-2 days at -70°C 
using Kodak XAR-5 films, and autoradiograms were scanned 
with a Bio-Rad (Richmond, CA) Video densitometer 620. The 
IGF-1-R probe was used as a control (2 gene copies) for 
densitometry and for the amount of DNA immobilized on the 
membrane. In our recent experience (Berns ef al., 1992) 
concerning measurement of c-niyc and HER21neu amplification 
in 975 breast tumours, the incidence for c-myc amplification 
was 17% and that of HER21neu amplification was 19% (these 
percentages are similar to average percentage values, reported 
by others). 
Statistics 
Associations between groups to be compared were assessed 
by the Spearman rank correlation test. Differences between 
groups were tested non-parametrically by the Wilcoxon 2-sam- 
ple test (Mann-Whitney U-test). 
RESULTS 
IGF-I-R uutoradiography 
In all samples, positivity for specific '251-IGF-1 binding was 
observed by IGF-1-R receptor autoradiography. Tissue sec- 
tions derived from ovarian adenocarcinomas showed increased 
density of IGF-1-R (1.5+ to 4+,  n = 37) when compared to 
normal ovarian tissues (1 +, n = 10). In tumours, high density 
of IGF-1-R was exclusively associated with epithelial tumour 
cells, while surrounding connective tissue was devoid of 
specific '251-IGF-I binding. Examples of autoradiograms of 2 
tumour tissues with stromal tissue are shown in Figure 1. 
In 71% (517) of the tumours with necrotic areas (7137), high 
expression of IGF-1-R was observed in these necrotic areas, 
whereas in 2 tumours necrotic areas were negative for specific 
'251-IGF-l binding. An example of Iz5I-IGF-l binding in a 
necrotic area, with histology, is shown in Figure 2. 
EGF-R, IGF-I-R, ER and PgR Scatchard-analysis 
The combined EGF-R and IGF-1-R receptor data with 
respect to median (+ range) and maximum binding capacities 
and apparent dissociation constants of the various tissue 
biopsies analyzed are listed in Table I. Fifty-three of the 82 
adenocarcinomas studied (65%) were positive for EGF-R by 
Scatchard analysis, with a median level of 17 fmolimg protein. 
The group of adenocarcinomas was composed of 6 subgroups 
with different histological classifications, and with respect to 
EGF-R levels, there were no significant differences between 
these various subgroups (Fig. 3a). In the combined group of 
benign tumours (5 cystadenomas, 1 adenofibroma) and border- 
line malignancies, 57% (8114) and, in the normal ovarian 
tissues, only 31% (51 16) were positive for EGF-R. There was a 
near-significant difference (2p = 0.06) between the EGF-R 
levels in adenocarcinomas and normal ovaries. Epithelial 
ovarian tumours might be expected to contain a higher 
FIGURE zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA1 rqponmlkjihgfedcbaZYXWVUTSRQP I- yxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAAutoradiographic localization of 1251-IGF-l receptors in ovarian cancer. zyxwvutsrqp nmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA(a 
and zyxwvuts qponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAd )  Total hinding; cryostat sections were incubated for 2 h r  at room emperature with 
]?'I-IGF-l. Autoradiograms show high density of labeling of epithelial tumour cells and low 
density of labeling on surrounding tissue. (6 andf) Haematoxylin-stained sections showing 
tumour tissue. (c) A higher magnification of the central part of the tissue in (b). (e) 
Non-specific binding, in semi-adjacent section of tumour shown in (d) .  
FtGURE 2 - Autoradiographic localization of '251-IGF-l receptors in necrotic ovarian 
tissue. (a) Total binding, cryostat sections were incubated for 2 hr  at room temperature with 
1251-IGF-l; autoradiogram shows high density of labeling of necrotic area. zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA(b) Haematoxylin- 
stained section showing necrotic area from (a). (c )  Higher magnification of the upper right 
part of (6). 
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TABLE zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAI xwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA- AMOllNTS OF ER. PER. ECF-R IGF-I-R, IN DIFFERENT OVARIAN TISSUES. AND DISSOCIATION CONSTANTS zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAOF EGF AND IGF-I BINDING 
Receptor type 
~- ____ 
ER: 
fmolimg protein 
(medianirange) zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA
9k positive(+) 
+: fmolimg protein 
(medianirange) 
PgR: 
fmolimg protein 
(medianirange) 
% positive (+ )  
+: fmolimg protein 
(medianirange) 
Adeno-ca 
19 (0-162) 
(n := 91) 
60% 
60 (1 1-162) 
(n == 55) 
5 (0-592) 
( n  =: 90) 
38% 
3.5 (1 1-592) 
(n =: 34) 
Benign + borderline 
6 (0-52) 
(n  = 15) 
47%, 
25 (14-52) 
(n = 7) 
33 (0-366) 
( n  = 15) 
73% 
83 (15-366) 
(n = 11) 
Normal 
10 (0-66) 
(n  = 19) 
53% 
24 (10-66) 
(n = 10) 
152 (0-310) 
( n  = 19) 
89% 
( n  = 16) 
160 (38-310) 
~ 
Other\ 
0 (0-1Y) 
(n  = 7) 
29% 
19(11 + 19) 
( n  = 2) 
16 (0-105) 
57% 
101 (16-105) 
( n  = 4) 
(I1 = 7) 
EGF-R:B,,4, 
(medianirange) (n == 82) (n = 14) (n = 16) (n = 4) 
+: fmolimg protein 24 (5-158) 33 (6-37) 39 (13-50) same as above 
(medianirange) (n  == 53) (n  = 8) (n  = 5) 
fmolimg protein 17 (0-158) 10 (0-37) 0 (0-50) 58 (55-62) 
%positive ( + )  65% 57% 31% 100% 
EGF- R: KL) 
(medianirange) (n =: 53) (n  = 8) (n  = zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA5 )  (n = 4) 
nM 0.9 * 0.3 0.6 -c 0.2 1.0 & 0.4 1.0 zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGF CBAt 0.1 
(mean t SD) 
IGF-R:B,,, 
fmolimg protein 64 (6-220) 30 (9-36) 26 (0-61) 88 (0-1 13) 
( median zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAi range ) ( n  =: 25) (n = 5) (n  = 10) (n = 5 )  
(medianirange) (n  = 9) (n  = 4) 
nM 0.9 (0.3-1.6) 0.6 (0.3-1.0) 1.1 (0.3-1.4) l(1.0-1.1) 
% positive (+ )  100% 100% 90% 80% 
+: fmolimg protein same as above same as above 26 (15-61) 113(36-113) 
IGF-R:KD 
nM 0.29 (0.11-0.78) 0.17 (0.12-0.41) 0.49 (0.12-0.82) 0.3 (0.25-0.39) 
(medianirange) (n =: 25) (n = 5 )  (n = 9) ( n  = 4) 
nM 0.34 2 0.17 0.21 2 0.12 0.45 f 0.22 0.31 t 0.06 
EGF- and IGF-1-receptor assays were performed with Scatchard analysis as described in the text. ER and PgR were measured by 
enzyme immunoassays. Composition of the various groups with respect to different histologically-confirmed subclasses is described in 
the “Patients” section. +: indicates median content and range, given for receptor-positive tumours only. 
percentage of cpithelial cells than normal ovaries. Therefore, 
i t  should be realized that the differences in EGF-R levels 
described may be biased. Four non-epithelial ovarian tumours 
(2, granulosa-cell turnours, 1 fibrothecoma and 1 MTI) con- 
tained high levels of EGF-R, with a median of 58 fmolimg 
protein. 
For IGF-1-R (Table I ) ,  higher levels of IGF-1-R were 
measured in membrane preparations of adenocarcinomas than 
in those of the combined group of benign tumours and 
borderline malignancies or those of  normal ovarian tissues. 
However, in contrast to what was observed for EGF-R, all 
adenocarcinoma and all combined benigniborderline samples 
analyzed wcrc positive for IGF-1-R by Scatchard analysis. 
Nine o u t  of  10 (90%) of the normal ovarian tissucs were 
positive for IGF-1-R. Four out of 5 non-epithelial ovarian 
tumours (2 granulosa-cell tumours, zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA2 fibrothecomas and 1 
MTI) containcd very high levels (median 88 fmol/mg protein) 
of IGF-I-R. In  agrcemcnt with the results of autoradiography 
on frozen scctions, the IGF-1-R levels, measured by Scatchard 
analysis, were higher in adenocarcinomas than in normal 
ovarian tissucs (median 64 zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAvs. 26 fmol/mg protein). Like the 
”’I-EGF binding in the various groups, the affinity (K,,) of 
‘2T-IGF-1 lor its receptor in the different tissues analyzed was 
not different (Table I). 
Cytosolic E R  and PgR data are given in Table I. Sixty 
percent of the adenocarcinoma tissues (55191) were positive 
for ER ( 2  10 fmol/mg protein), hith a median level of 19 
fmolimg protein. In thc combined group of benign/borderlinc 
tumours 37% and among the normal ovarian tissues 53% were 
ER-positive. Only 29% of the non-epithelial ovarian tissues (2 
out of 7) were ER-positive. The E R  levels were not signifi- 
cantly different when adcnocarcinomas were compared with 
either henign/borderline turnours or normal ovarian tissue. 
However, E R  levels were higher in serous than in mucinous 
adenocarcinornas (2p = 0.001; Fig. 3b). When the E R  levels of 
serous or mucinous adenocarcinomas were compared with the 
combined group of other adenocarcinomas, therc was a 
near-significant lower or higher level, respectively, in the latter 
group of tumours (serous vs. others, 2p = 0.06 and mucinous 
vs. others, 2p = 0.07). 
Thirty-eight percent (34/90) of the adenocarcinomas tissues 
were positive for PgR ( 2  10 fmolimg protein). Of the benign/ 
borderline tumours 73% and of the normal tissues 89% were 
positive. Most pronounced was the observed differencc in the 
median of thc measured PgR levels, decreasing from 152 fmol 
mgiprotein in normal tissues, via 33 fmolimg protein in 
benign/borderline tissues, to 5 frnolimg protein in adenocarci- 
nomas (Table I ) .  These differences were significant for all 
groups studied (adenocarcinomas vs. benigniborderline, 
2p = 0.0012; adenocarcinomas vs. normal ovaries, 2p < 0.0001 
and benigniborderline w. normal ovaries, 2p = 0.018). The 
levels of PgR in the 6 histologic subgroups of adenocarcinomas 
did not differ (Fig. 3c). 
In addition, for these adenocarcinoma samples, Spearman 
regression analysis did not reveal a significant correlation 
between the levels of EGF-R and E R  and of EGF-R and PgR 
values. whereas there was a weak positive relationship 
222 zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBABERNS zyxwvutsrqponmlkjihgfedcba XWVUTSRQPONMLKJIHGFEDCBAETAL. zyxwvutsrqponmlkjihgfedcbaZY VUTSRQPONMLKJIHGFEDCBA
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FIGURE zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA3-Levels of EGF-R (a), ER (b) and PgR (c) in 6 
histological subgroups of ovarian adenocarcinomas. Horizontal 
line indicates the median value of the respective receptors. 
(Rs = 0.25, n = 90; 2p < 0.05) between the levels of ER and 
PgR. 
Gene amplification 
Twenty-five different DNA samples isolated from adenocar- 
cinorna tissues (14 serous, 4 mucinous, 3 endometrioid, 1 
clear-cell, and 3 mixed turnours) were analysed by Southern 
blotting for amplification or rearrangement of the EGF-R, 
IGF-I-R, c-myc, and HER2irieii genes. No rearrangement for 
any of the genes studied in EcoR1-digested DNAs was 
obscrvcd. No amplification (more than 2 gene copies) of the 
EGF-R and IGF-R gene was noted (Fig. 4). Amplification of 
FIGURE 4 -  Southern blot of DNA from ovarian adenocarci- 
noma tissue samples. Total DNA was digested with EcoR1, 
subjected to electrophoresis, transferred to a nylon membrane and 
hybridized with c-myc, HER2ineii and IGF-1-R simultaneously. 
Filters were washed at high stringency and exposed for 2 days, as 
described in the text. In lanes 22, 23 and 15 amplified oncogenes 
are shown. 
the c-niyc gene was found in DNAs from 7 (28%) adenocarci- 
nomas. The tumours which contained an amplified c - tyc  gene 
were all negative for cytosolic PgR, whereas 5 of these turnours 
were positive for ER.  The c-myc amplifications were found in 1 
mucinous (10 copies), 1 endometrioid (10 copies), 1 mixed (10 
copies), and 4 serous turnours (1 X 10 and 3 x 5 copies). 
HER2ineu amplifications were only obsqrved in DNA samples 
isolated from 2 ( 5  and 10 copies) of the 3 histologically 
confirmed endometrioid tumours studied. The othcr 22 sam- 
ples analysed contained diploid amounts of the HER2ineu 
gene. Figure 4 shows an example of an autoradiogram of 
EcoRI-digested DNAs probed with a mixture of c-nzyc, HER?/ 
m i  and IGF-I-R probes. One of the 3 mucinous samples 
analysed showed a co-amplification of the c-myc and HER21 zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA
neu genes. 
DISCUSSION 
We have shown that the levels of EGF-R, IGF-1-R, ER,  
PgR and gene copy numbers of HER2/rzrri and c-myc vary in 
ovarian adenocarcinoma, benigniborderline malignancies and 
normal ovarian tissue. 
The median levels of IGF-1-R and E R  are approximately 
twice as high in ovarian adenocarcinoma as in normal ovarian 
tissue. In contrast, the median level of PgR was about 30 times 
lower in ovarian adenocarcinoma than in normal ovarian 
tissue. The frequency of receptor positivity for E R  and 
IGF-I -R was similar in normal, benigniborderline and adeno- 
carcinoma tissues. On the other hand, EGF-R levels were 
increased (from 31% to 57% to 65%, respectively), and PgR 
levels were decreased (from 89% to  73% to 38%). respectively). 
The few cases of non-epithelial tumours studied showed high 
levels of both EGF-R and IGF-1-R, with low levels of E R  and 
PgR. In breast cancer, higher levels and incidence of IGF-1-R 
when compared to benign and normal breast tissue have also 
been reported (Pekonen zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAet al., 1988; Peyrat et zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBANI., 1988). Our 
autoradiographical analyses revealed that the increased 
amounts of IGF-1-R are mainly associated with epithelial 
tumour cells of the ovarian adenocarcinomas, and sometimes 
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with necrosis. The (biological) significance of specific 12sI- 
IGF-1 binding to these necrotic areas is not clear. It may 
indicate rapidly growing tumours with insufficient vasculariza- 
tion. In human breast-cancer tissues, specific 12sI-EGF binding 
has also been observed in necrotic areas by zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAin xwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAvitro autoradiog- 
raphy (Rcubi and Torhorst, 1988). This specific binding of 
growth factors in necrotic tissue indicates the need for histolog- 
ical examination of growth-factor binding and could be useful 
in predicting a possible heterogeneity of responses of the 
patient to (future) growth-factor antagonist therapy and/or zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA
growth-factor/growth-factor-receptor blocking therapy. 
Likc Bauknecht et zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAa/. (1990) and Zhangetal. (1989), we also 
obscrvcd that the EGF-R gene is not frequently amplified in 
ovarian tissues. Sincc the IGF-1-R gene is also not amplified, 
we conclude that amplification of these genes is not involved in 
ovarian carcinogenesis. However, amplification (20-2696) of 
the HER2ineu gene (another member of the erbB family) has 
been reported in ovarian cancer by Zhang z xwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBAet al. (1989) and 
Slamon et al. (1989), but we (like Zhou et al., 1988) observed in 
only 2 cases (8%) an amplification of the HER2/neii gene, each 
time in cndomctrioid adenocarcinomas. This suggests that 
routine analysis of HER2/ncu amplification in all ovarian 
adenocarcinomas may be clinically irrelevant but on the other 
hand the prognostic significance of HER2/neu amplification is 
still unclear. 
Amplification of another important oncogene, the c-nzyc 
gene, was observed in 7 out of 25 adenocarcinoma-DNAs 
(28%) studied. This incidence is similar to that observed by 
Zhou et a/. (1988) and Baker e f  nl. (1990). 25% and 29% 
amplification respectively, whereas in contrast Smith et al. 
(1989) did not find any amplification in their study. The c-nzyc 
amplifications described in our study may be associated with 
PgR-negativity, since all 7 tumours with an amplified c-nzyc 
gene werc negative for cytosolic PgR, in spite of ER-positivity 
in 5 of these 7 cases. Similar results were described for breast 
canccr, wherc c-nyc amplification was also found to be 
strongly associatcd with absence of the progesterone receptor 
(Bernsefal., 1992). 
Although there are similarities between breast and ovarian 
cancer (as described above), the present data show that there 
are differences as well. In the total group of ovarian adenocar- 
cinomas, we found n o  negative relationship betwcen EGF-R 
and E R  or PgR (cstahlished by Spearman regression analysis) 
as observed in breast cancer. This is puzzling, since there is a 
large body of literature showing a negative relationship be- 
tween EGF-R and E R  or PgR in human breast-tumour 
biopsies (Klijn et al., 1992). Also as a prognosticator of survival 
and response to endocrine therapy, there is a disparity regard- 
ing the presence of prognostic significance of E R  in breast 
cancer, and the absence of prognostic value of ER in ovarian 
cancer (Rao and Slotman, 1991). On the other hand, the levcls 
of the oestrogen-regulated PgR appear to be of prognostic 
value in both ovarian carcinoma (Rao and Slotman, 1991) and 
breast cancer (Foekens et zyxwvutsrqpo l jihgfedcbaZYXWVUTSRQPO LKJIHGFEDCBAd., yxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA101). From these data we 
suggest that the role of the oestrogcn receptor may be different 
in ovarian and in breast cancer. In ovarian cancer chromosome 
6q, the locus of the ER is often affected (Zhcng et al., 1991). 
Furthermore, the expression of pS2, an oestrogen-regulated 
protein in breast cancer, is negative or low in ovarian cancers 
as measured by immuno-radiometric assays for pS2 (Foekens 
ef al., 1990). Moreover, mRNA expression of pS2 appeared to 
be poorly correlated with E R  in ovarian carcinomas (Wysocki 
et al., 1990). It would therefore be of intcrest to study the 
expression of other ER-regulated genes, like cathepsin D, in 
ovarian cancer, to obtain more insight into ovarian carcinogen- 
esis and biology. Indeed, in a recent report (Scambia et al., 
1991) it  was suggested that cathcpsin D was not correlated 
with E R  expression. 
The determination of possible prognostic or therapeutic 
significance of gene amplification or over-expression and 
growth-factor receptors (EGF-R) in ovarian cancer, as de- 
scribed by Bauknecht et al. (1990). is currcntly under investiga- 
tion. 
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